Literature DB >> 12002273

Effect of phosphodiesterase inhibitors on nitric oxide production by glial cells.

Minka Yoshikawa1, Akio Suzumura, Atsushi Ito, Tsukasa Tamaru, Tetsuya Takayanagi.   

Abstract

Nitric oxide (NO) is considered to play a crucial role in the development of various pathological processes in the CNS, such as neuronal degeneration, inflammation and demyelination. In order to search for the agents which suppress NO production in the CNS, we examined the effects of one of the agents which elevate cyclic AMP production, phosphodiesterase inhibitors (PDEIs), on NO production by glial cells in vitro. All the types of PDEIs, from type I- to V-specific and non-specific, suppressed the production of NO by mouse microglia and astrocytes stimulated with lipopolysaccharide, in a dose-dependent manner. Suppression of inducible NO synthase by PDEIs was confirmed by the expression of mRNA by RT-PCR. Although it required 10 microM or higher concentration to effectively suppress NO production in vitro, certain combinations of three different PDEIs synergistically suppressed NO production by astrocytes at 1 microM which could be obtained in vivo at usual therapeutic doses. Similary, combinations of three PDEIs at 1 microM synergistically increased intracellular cAMP in astrocytes. The suppressive effects of PDEIs on NO production were abolished by addition of tumor necrosis factor alpha (TNFalpha). Thus, the main suppression mechanism of NO might be indirect through suppression of TNFalpha. Since some PDEIs are reported to pass through the blood-brain-barrier, the combination of three PDEIs may be worth trying in neurological diseases, such as multiple sclerosis, human immunodeficiency virus-related neurological diseases and other neurodegenerative disorders in which NO may play a crucial role.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12002273     DOI: 10.1620/tjem.196.167

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  8 in total

1.  Enhancement of the anti-inflammatory and anti-arthritic effects of theophylline by a low dose of a nitric oxide donor or non-specific nitric oxide synthase inhibitor.

Authors:  Adel Gomaa; Mohsen Elshenawy; Noha Afifi; Eman Mohammed; Romany Thabit
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

2.  Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases.

Authors:  Won-Kyo Jung; Da-Young Lee; Cheol Park; Yung Hyun Choi; Inhak Choi; Sae-Gwang Park; Su-Kil Seo; Soo-Woong Lee; Sung Su Yea; Soon-Cheol Ahn; Chang-Min Lee; Won Sun Park; Jae-Hong Ko; Il-Whan Choi
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

3.  Vasoactive neuropeptides in clinical ophthalmology: An association with autoimmune retinopathy?

Authors:  Donald R Staines; Ekua W Brenu; Sonya Marshall-Gradisnik
Journal:  Clin Ophthalmol       Date:  2009-06-02

4.  Pharmacological studies on the anti-inflammatory and immunomodulatory role of pentoxifylline and its interaction with nitric oxide (NO) in experimental arthritis in rats.

Authors:  Rishi Pal; Manju J Chaudhary; Prafulla Chandra Tiwari; Rajendra Nath; Suresh Babu; Kamlesh Kumar Pant
Journal:  Inflammopharmacology       Date:  2016-09-26       Impact factor: 4.473

5.  Nitric oxide release from trigeminal satellite glial cells is attenuated by glial modulators and glutamate.

Authors:  Jens Christian Laursen; Brian Edwin Cairns; Ujendra Kumar; Rishi Kumar Somvanshi; Xu-Dong Dong; Lars Arendt-Nielsen; Parisa Gazerani
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-12-15

6.  Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production.

Authors:  Cinzia Dello Russo; Anne I Boullerne; Vitaliy Gavrilyuk; Douglas L Feinstein
Journal:  J Neuroinflammation       Date:  2004-06-30       Impact factor: 8.322

7.  Does autoimmunity of endogenous vasoactive neuropeptides cause retinopathy in humans?

Authors:  Donald R Staines
Journal:  Med Hypotheses       Date:  2007-06-07       Impact factor: 1.538

Review 8.  Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target.

Authors:  Nadia Alice Vieira Motta; Lis Jappour Autran; Stephani Correia Brazão; Rosane de Oliveira Lopes; Christianne Brêtas Vieira Scaramello; Gabriel Ferreira Lima; Fernanda Carla Ferreira de Brito
Journal:  Int Immunopharmacol       Date:  2020-12-28       Impact factor: 5.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.